Are there specific patient populations who are at higher risk for adverse effects from ixekizumab?

Featuring Joel Gelfand, MD, MSCE, FAAD |

Penn Medicine

Director, Psoriasis and Phototherapy Treatment Center

Director, Center for Clinical Sciences in Dermatology

Philadelphia, Pennsylvania

| Published November 01, 2024